Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir.

Best BM, Letendre SL, Koopmans P, Rossi SS, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, McCutchan JA, Morgello S, Simpson DM, Capparelli EV, Ellis RJ, Grant I; CHARTER Study Group..

J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):376-81. doi: 10.1097/QAI.0b013e318247ec54.

2.

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.

Best BM, Koopmans PP, Letendre SL, Capparelli EV, Rossi SS, Clifford DB, Collier AC, Gelman BB, Mbeo G, McCutchan JA, Simpson DM, Haubrich R, Ellis R, Grant I; CHARTER Group..

J Antimicrob Chemother. 2011 Feb;66(2):354-7. doi: 10.1093/jac/dkq434. Epub 2010 Nov 23.

3.

A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel.

Schwartz JL, Rountree W, Kashuba AD, Brache V, Creinin MD, Poindexter A, Kearney BP.

PLoS One. 2011;6(10):e25974. doi: 10.1371/journal.pone.0025974. Epub 2011 Oct 19.

4.

Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.

Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR, Harris DR, Havens PL; Adolescent Trials Network for HIV/AIDS Interventions..

Antimicrob Agents Chemother. 2008 Feb;52(2):631-7. Epub 2007 Nov 19.

5.

ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.

Manosuthi W, Sukasem C, Thongyen S, Nilkamhang S, Sungkanuparph S.

J Antimicrob Chemother. 2014 Aug;69(8):2195-201. doi: 10.1093/jac/dku129. Epub 2014 Apr 30.

PMID:
24788661
6.

Low atazanavir concentrations in cerebrospinal fluid.

Best BM, Letendre SL, Brigid E, Clifford DB, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Simpson DM, Ellis R, Capparelli EV, Grant I; CHARTER Group..

AIDS. 2009 Jan 2;23(1):83-7. doi: 10.1097/QAD.0b013e328317a702.

7.

Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.

Dumond JB, Nicol MR, Kendrick RN, Garonzik SM, Patterson KB, Cohen MS, Forrest A, Kashuba AD.

Clin Pharmacokinet. 2012 Dec;51(12):809-22. doi: 10.1007/s40262-012-0012-y.

8.
9.

Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment.

Kearney BP, Yale K, Shah J, Zhong L, Flaherty JF.

Clin Pharmacokinet. 2006;45(11):1115-24.

PMID:
17048975
11.

Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection.

Duwal S, Schütte C, von Kleist M.

PLoS One. 2012;7(7):e40382. doi: 10.1371/journal.pone.0040382. Epub 2012 Jul 11. Erratum in: PLoS One. 2012;7(11). doi:10.1371/annotation/fb73d0f4-1cd8-481d-bddd-20439896102a.

12.

Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.

Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, Rezk NL, Bridges AS, Stewart PW, Cohen MS, Kashuba AD.

AIDS. 2007 Sep 12;21(14):1899-907.

13.

Atazanavir pharmacokinetics with and without tenofovir during pregnancy.

Mirochnick M, Best BM, Stek AM, Capparelli EV, Hu C, Burchett SK, Rossi SS, Hawkins E, Basar M, Smith E, Read JS; IMPAACT 1026s Study Team..

J Acquir Immune Defic Syndr. 2011 Apr 15;56(5):412-9. doi: 10.1097/QAI.0b013e31820fd093.

14.

Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.

Kashuba AD, Gengiah TN, Werner L, Yang KH, White NR, Karim QA, Abdool Karim SS.

J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):264-9. doi: 10.1097/QAI.0000000000000607.

15.

The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.

Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, Delahunty T, Bushman LR, Fletcher CV.

Clin Pharmacol Ther. 2008 Feb;83(2):265-72. Epub 2007 Jun 27.

PMID:
17597712
16.

Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study.

Chen J, Flexner C, Liberman RG, Skipper PL, Louissaint NA, Tannenbaum SR, Hendrix CW, Fuchs EJ.

J Acquir Immune Defic Syndr. 2012 Dec 15;61(5):593-9. doi: 10.1097/QAI.0b013e3182717c98.

17.

Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.

Baheti G, King JR, Acosta EP, Fletcher CV.

AIDS. 2013 Jan 14;27(2):221-5. doi: 10.1097/QAD.0b013e32835a9a2d.

18.

Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.

Flynn PM, Mirochnick M, Shapiro DE, Bardeguez A, Rodman J, Robbins B, Huang S, Fiscus SA, Van Rompay KK, Rooney JF, Kearney B, Mofenson LM, Watts DH, Jean-Philippe P, Heckman B, Thorpe E Jr, Cotter A, Purswani M; PACTG 394 Study Team..

Antimicrob Agents Chemother. 2011 Dec;55(12):5914-22. doi: 10.1128/AAC.00544-11. Epub 2011 Sep 6.

19.

The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards.

Delahunty T, Bushman L, Robbins B, Fletcher CV.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jul 1;877(20-21):1907-14. doi: 10.1016/j.jchromb.2009.05.029. Epub 2009 May 21.

20.

Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1.

Croteau D, Letendre S, Best BM, Ellis RJ, Breidinger S, Clifford D, Collier A, Gelman B, Marra C, Mbeo G, McCutchan A, Morgello S, Simpson D, Way L, Vaida F, Ueland S, Capparelli E, Grant I; CHARTER Group..

Antimicrob Agents Chemother. 2010 Dec;54(12):5156-60. doi: 10.1128/AAC.00507-10. Epub 2010 Sep 27.

Supplemental Content

Support Center